PCM
PCVX icon

Pentwater Capital Management’s Vaxcyte PCVX Stock Holding History

Pentwater Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,000
Closed -$221K – 237
2020
Q2 		$221K Buy
+7,000
New +$225K ﹤0.01% 147

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pentwater Capital Management's PCVX Position: Q3 2020 in Review

Pentwater Capital Management sold out of Vaxcyte (PCVX) in Q3 2020, closing a stake of 7,000 shares — an estimated $221K sold.

Pentwater Capital Management first reported a position in PCVX in Q2 2020 and held it in 1 quarter. The position peaked at $221K in Q2 2020. 60 funds tracked by Wall St. Rank hold PCVX as of Q3 2020.

  • Pentwater Capital Management reported no remaining Vaxcyte position as of Q3 2020 after selling out during the quarter.
  • Pentwater Capital Management sold 7,000 Vaxcyte shares in Q3 2020, an estimated $221K.
  • Pentwater Capital Management first reported a position in Vaxcyte in Q2 2020 and held it in 1 quarter.
  • Pentwater Capital Management's Vaxcyte position peaked at $221K in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2020.

Based on Pentwater Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.